Development and characterization of functionalized niosomes for brain targeting of dynorphin-B.
A niosomal formulation, functionalized with N-palmitoylglucosamine, was developed as potential brain targeted delivery system of dynorphin-B. In fact, this endogenous neuropeptide, selective agonist of k opioid receptors, is endowed with relevant pharmacological activities on the central nervous system, including a marked antinociceptive effect, but is unable to cross the blood brain barrier (BBB), thus requiring intracerebroventricular administration. Statistical design of experiments was utilized for a systematic evaluation of the influence of variations of the relative amounts of the components of the vesicle membrane (Span 60, cholesterol and SolulanC24) on vesicle mean diameter, polydispersity index and drug entrapment efficiency, chosen as the responses to optimize. A Scheffé simplex-centroid design was used to obtain the coefficients of the postulated mathematical model. The study of the response surface plots revealed that variations of the considered factors had different effects on the selected responses. The desirability function enabled for finding the optimal mixture composition, which represented the best compromise to simultaneously optimize all the three responses. The experimental values obtained with the optimized formulation were very similar to the predicted ones, proving the validity of the proposed regression model. The optimized niosomal formulation of dynorphin-B administered intravenously to mice (100mg/kg) showed a pronounced antinociceptive effect, significantly higher (P<0.05) than that given by i.v. administration of the simple solution of the peptide at the same concentration, proving its effectiveness in enabling the peptide brain delivery. These positive results suggest that the proposed approach could be successfully extended to other neuro-active peptides exerting a strong central action, even at low doses, but unable to cross the BBB.
Department of Chemistry, University of Florence, Firenze, Italy.
M
M
Bragagni
Department of Chemistry, University of Florence, Firenze, Italy. Electronic address: nmennini@unifi.it.
N
N
Mennini
Department of Chemistry, University of Florence, Firenze, Italy.
S
S
Furlanetto
Department of Chemistry, University of Florence, Firenze, Italy.
S
S
Orlandini
Department of NEUROFARBA, University of Florence, Firenze, Italy.
C
C
Ghelardini
Department of Chemistry, University of Florence, Firenze, Italy.
P
P
Mura
D000700:Analgesics / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004355:Drug Stability; D004399:Dynorphins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D004723:Endorphins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006017:Glycolipids / Q000138:chemical synthesis / Q000737:chemistry*; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008081:Liposomes; D008297:Male; D051379:Mice; D010146:Pain / Q000188:drug therapy / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000819:agonists
D000700:Analgesics; D004337:Drug Carriers; D004723:Endorphins; D006017:Glycolipids; D008081:Liposomes; C000594385:N-palmitoylglucosamine; D017473:Receptors, Opioid, kappa; D004399:Dynorphins; C036200:rimorphin
Brain targeting; Design of experiments; Dynorphin-B; Glucose-bearing niosomes; Hot plate latency test; Response surface study